- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Raises Concerns About Accuracy of Insulin Dosing Apps
The study, conducted by the Global eHealth Unit at the Imperial College London, has found that the majority of insulin dosing apps are unreliable and put patients at risk of getting incorrect doses of insulin. Does this demand an FDA oversight of the apps?
A recent study led by the Global eHealth Unit at the Imperial College London has found that the majority of insulin dosing apps are unreliable and put patients at risk of getting incorrect doses of insulin.
For patients on insulin, meal-time dosing of short-acting insulin is a challenging task. There are a lot of factors that go in to deciding how much insulin to administer—anticipated carbohydrate intake, premeal blood sugar, planned activities afterwards, and more. A simple calculator app to help out seems like a no-brainer. And there are a lot of apps out there that claim to do that.
Huckvale and colleagues found 46 insulin dose calculator apps in the app stores. When they evaluated these apps, they found some pretty concerning patterns.
Read the complete article on MedpageToday: http://bit.ly/1PIpbOI
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
